A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT02219490 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1596

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Interventions

DRUG: ABT-450/r/ABT-267
DRUG: ABT-333
DRUG: Ribavirin (RBV)

Sponsor

AbbVie